Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to CetuximabFerdows Ather, Steven Wong|PLoS ONE|2013Cited by 35